Ever since the Women’s Health Initiative (WHI) study was halted due to concerns of increased risk for breast cancer associated with hormone therapy use, postmenopausal women and their doctors have had to weigh the risks and benefits of such therapies. Dr. Campos-Outcalt discusses the latest findings from long-term follow-up of WHI participants, providing context for patient-provider decision-making.
